MedTrace Logo

Safety and Efficacy of KER-065 in Participants With Duchenne Muscular Dystrophy

NCT07704099 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2026-08-10

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and efficacy of KER-065 administered to adult and pediatric ambulatory and nonambulatory male participants with Duchenne Muscular Dystrophy (DMD) on stable background therapy.

Conditions

Interventions

DRUG

KER-065

KER-065 will be administered subcutaneously (SC)

Sponsors & Collaborators

  • Keros Therapeutics, Inc.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
9 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-09-14
Primary Completion
2029-07-17
Completion
2029-08-14
FDA Drug
Yes

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07704099 on ClinicalTrials.gov